What is Adaptive Biotechnologies?
Immune medicine and MRD diagnostics company with $277.0M 2025 revenue; $70.9M Q1 2026 revenue scale.
- Category
- Immune medicine and MRD diagnostics
- Headquarters
- Seattle, WA
- Founded
- 2009
- Employees
- 750+
- Total funding
- Public company; not venture-round led
- Status
- Nasdaq: ADPT
What is Adaptive Biotechnologies?
Adaptive Biotechnologies is a Immune medicine and MRD diagnostics company headquartered in Seattle, WA. As of June 2026, its clearest scale signal is $277.0M 2025 revenue; $70.9M Q1 2026 revenue.
Adaptive Biotechnologies operates a commercial-stage immune-medicine company focused on MRD testing, immune sequencing, pharma services, and clinical products built on adaptive immune receptor data. Its core customer set includes oncologists, hematologists, clinical labs, biopharma partners, academic researchers, payers, and patients, and its public product surface includes clonoSEQ, MRD testing, immunoSEQ, TCR and BCR sequencing, Pharma services. The current scale signal is $277.0M 2025 revenue; $70.9M Q1 2026 revenue, which makes this a mid-market public account with real enterprise procurement capacity rather than an early-stage startup.
The company competes where healthcare buyers care about evidence, reliability, compliance, integrations, and measurable operational or clinical outcomes. Vendor evaluation usually involves business owners plus finance, security, legal, procurement, data, clinical, quality, compliance, and IT stakeholders.
For sellers, the account should be approached as a public-company buying center. The strongest angles connect directly to growth, retention, margin expansion, reimbursement, quality, member or patient experience, regulated data handling, workflow automation, or lower cost to serve.
What does Adaptive Biotechnologies offer?
Adaptive Biotechnologies offers clonoSEQ, MRD testing, immunoSEQ, TCR and BCR sequencing and related healthcare workflows.
- clonoSEQ· Core product
- MRD testing· Core product
- immunoSEQ· Core product
- TCR and BCR sequencing· Workflow
- Pharma services· Workflow
- Immune medicine platform· Workflow
- Data products· Platform
- Clinical development partnerships· Platform
How does Adaptive Biotechnologies make money?
Adaptive earns clinical testing, pharma services, sequencing, milestone, and collaboration revenue, with MRD volume and reimbursement as the core growth drivers.
Adaptive earns clinical testing, pharma services, sequencing, milestone, and collaboration revenue, with MRD volume and reimbursement as the core growth drivers. Growth is driven by the same operating levers buyers track internally: customer volume, recurring revenue, utilization, reimbursement, renewal rates, attach rates, product expansion, and disciplined cost control.
Diagnostic economics depend on test type, Medicare and commercial reimbursement, pharma contracts, regulatory milestones, sample volume, and services scope rather than public list prices. In practice, commercial packaging usually separates strategic enterprise accounts, standard commercial customers, implementation services, support, usage, and renewal economics.
For a seller, budget access depends on showing a near-term connection to revenue capture, margin improvement, compliance, uptime, provider or member experience, data quality, clinical evidence, or workflow throughput. Generic efficiency claims are weaker than quantified impact on one of those operating levers.
Who leads Adaptive Biotechnologies?
Adaptive Biotechnologies is led by Chad Robins, with finance, product, clinical, technology, commercial, and operations leaders influencing major vendor decisions.
- Chad RobinsCo-founder and Chief Executive OfficerCEO since foundingLeads immune medicine platform strategy.
- Tycho PetersonChief Financial OfficerCFOOwns finance, investor relations, and capital allocation.
- Harlan RobinsCo-founder and Chief Scientific OfficerCo-founderLeads scientific platform and immune-repertoire expertise.
- Nitin SoodChief Commercial OfficerCommercial leaderLeads MRD commercialization and market access.
How do you contact Adaptive Biotechnologies's leadership?
Adaptive Biotechnologies publishes an official investor-relations or corporate contact route, but this profile does not present guessed personal executive emails as verified. Use the official contact listed here, the company contact page, or a relationship-based introduction for executive outreach.
ir@adaptivebiotech.com (official published/company IR contact); personal executive format not verifiedHow much funding has Adaptive Biotechnologies raised?
Adaptive Biotechnologies is a public company (Nasdaq: ADPT), so the current capital story is public-market status, operating cash flow, debt or equity access, and acquisitions rather than a private startup round stack.
2009: Founded - Adaptive is founded to read the adaptive immune system. 2019: IPO - Adaptive lists on Nasdaq under ADPT. 2020: MRD commercialization expands - clonoSEQ grows as a measurable residual disease test. 2025: Full-year results - Adaptive reports $277.0M of 2025 revenue, including MRD growth and Immune Medicine revenue. 2026: Q1 results - Adaptive reports $70.9M of Q1 revenue and 32,595 clonoSEQ tests delivered.
As of June 2026, Adaptive Biotechnologies's practical funding capacity is best read through Nasdaq: ADPT, $277.0M 2025 revenue; $70.9M Q1 2026 revenue, its latest annual or quarterly filings, cash flow, balance sheet, and guidance. For public mid-market healthcare companies, the next budget cycle is usually governed by operating plans and investor commitments, not by a new venture round.
Seller signal: public-company status gives Adaptive Biotechnologies access to mature procurement and repeat budget cycles, but it also raises the proof bar. Successful pitches need a measurable business case, clean implementation plan, security and compliance readiness, and executive sponsorship from the functional owner.
How did Adaptive Biotechnologies get here?
Adaptive Biotechnologies grew through founding, product expansion, public-market milestones, and its latest June 2026 operating update.
- 2009Company foundedAdaptive begins around immune receptor sequencing.
- 2018clonoSEQ authorizationThe MRD test gains regulatory traction.
- 2019Public listingAdaptive becomes a public company.
- 2022MRD focusThe company increasingly focuses commercial execution on clonoSEQ.
- 2025MRD revenue growthMRD revenue reaches $212.3M for 2025.
- 2026Q1 test volume growthclonoSEQ test volume grows 41% year over year in Q1 2026.
Who are Adaptive Biotechnologies's competitors?
Adaptive Biotechnologies competes with public companies, private healthcare platforms, software vendors, services firms, and specialized workflow providers depending on the buyer's problem.
- NateractDNA and MRD testing competitor.
- Guardant HealthLiquid biopsy and cancer-diagnostics competitor.
- Exact SciencesCancer diagnostics and precision-oncology testing competitor.
- TempusPrecision-medicine diagnostics, data, and AI competitor.
- PersonalisPersonalized cancer MRD testing competitor.
- NeoGenomicsOncology lab and molecular-testing competitor.
Adaptive Biotechnologies — frequently asked questions
